Table 3.
Netleague laboratory-confirmed influenza: children.
| placebo | 0.55 (0.36, 0.83) | 0.13 (0.03, 0.51) | 0.5 (0.21, 1.19) | 0.28 (0.19, 0.41) | 0.71 (0.21, 2.4) |
|---|---|---|---|---|---|
| 1.81 (1.2, 2.77) | 3-IIV | 0.23 (0.06, 0.87) | 0.9 (0.35, 2.4) | 0.52 (0.32, 0.82) | 1.28 (0.35, 4.7) |
| 7.96 (1.98, 32.92) | 4.4 (1.15, 17.03) | 3-IIV MF59/AS03-adj | 3.97 (0.77, 21.01) | 2.27 (0.54, 9.38) | 5.64 (0.88, 36.6) |
| 2 (0.84, 4.76) | 1.11 (0.42, 2.88) | 0.25 (0.05, 1.3) | 4-IIV | 0.57 (0.22, 1.44) | 1.42 (0.32, 6.38) |
| 3.51 (2.46, 5.17) | 1.94 (1.22, 3.15) | 0.44 (0.11, 1.85) | 1.76 (0.7, 4.6) | 3-LAIV | 2.49 (0.7, 9.08) |
| 1.41 (0.42, 4.81) | 0.78 (0.21, 2.82) | 0.18 (0.03, 1.13) | 0.7 (0.16, 3.15) | 0.4 (0.11, 1.42) | 4-LAIV |
The estimate is located at the intersection of the column-defining vaccine and the row-defining vaccine. Data are RRs (95% CrI). Significant results are in bold.
In the upper triangle, comparison of treatments should be read from right to left. An RR below 1 favors the medication on the bottom right vs. the medication on the top left in the diagonal. E.g., RR 0.55 (95% CrI 0.36–0.83) indicates a significant reduction in the incidence of laboratory-confirmed influenza for the trivalent inactivated vaccine (3-IIV) compared with placebo/ no vaccination.
In the bottom triangle, comparison of treatments should be read from left to right. An RR below 1 favors the medication on the top left vs. the medication on the bottom right in the diagonal. E.g., RR 0.25 (95% CrI 0.05–1.3) indicates a non-significant reduction in the incidence of laboratory-confirmed for the trivalent inactivated adjuvanted with MF59/AS03 intramuscular vaccine (3-IIV MF59/AS03-adj) compared with the quadrivalent inactivated intramuscular (4-IIV).
Abbreviations: Placebo: placebo/ no vaccination; 3-IIV: trivalent inactivated intramuscular; 3-IIV MF59/AS03-adj: trivalent inactivated adjuvanted with MF59/AS03 intramuscular; 4-IIV: quadrivalent inactivated intramuscular; 3-LAIV: trivalent live-attenuated intranasal; 4-LAIV: quadrivalent live-attenuated intranasal.